Phase II Multi Center Study Investigating Translational Science in Chemotherapy-Naive Patients with Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) treated with the EGFR-TKI, Erlotinib (SPECS) (SPORE).

Trial Profile

Phase II Multi Center Study Investigating Translational Science in Chemotherapy-Naive Patients with Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) treated with the EGFR-TKI, Erlotinib (SPECS) (SPORE).

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Erlotinib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms SPECS
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2011 Planned End Date changed from 1 Jan 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top